PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma

Noll, Jacqueline E.; Vandyke, Kate; Hewett, Duncan R.; Mrozik, Krzysztof M.; Bala, Rachel J.; Williams, Sharon A.; Kok, Chung H.; Zannettino, Andrew C. W.
October 2015
Journal of Hematology & Oncology;10/7/2015, Vol. 8 Issue 1, p1
Academic Journal
Background: Multiple myeloma (MM) is an incurable haematological malignancy characterised by the clonal proliferation of malignant plasma cells within the bone marrow. We have previously identified pituitary tumour transforming gene 1 (Pttg1) as a gene that is significantly upregulated in the haematopoietic compartment of the myeloma-susceptible C57BL/KaLwRij mouse strain, when compared with the myeloma-resistant C57BL/6 mouse. Over-expression of PTTG1 has previously been associated with malignant progression and an enhanced proliferative capacity in solid tumours. Methods: In this study, we investigated PTTG1 gene and protein expression in MM plasma cells from newly diagnosed MM patients. Gene expression profiling was used to identify gene signatures associated with high PTTG1 expression in MM patients. Additionally, we investigated the effect of short hairpin ribonucleic acid (shRNA)-mediated PTTG1 knockdown on the proliferation of the murine myeloma plasma cell line 5TGM1 in vitro and in vivo. Results: PTTG1 was found to be over-expressed in 36-70 % of MM patients, relative to normal controls, with high PTTG1 expression being associated with poor patient outcomes (hazard ratio 2.49; 95 % CI 1.28 to 4.86; p = 0.0075; log-rank test). In addition, patients with high PTTG1 expression exhibited increased expression of cell proliferation-associated genes including CCNB1, CCNB2, CDK1, AURKA, BIRC5 and DEPDC1. Knockdown of Pttg1 in 5TGM1 cells decreased cellular proliferation, without affecting cell cycle distribution or viability, and decreased expression of Ccnb1, Birc5 and Depdc1 in vitro. Notably, Pttg1 knockdown significantly reduced MM tumour development in vivo, with an 83.2 % reduction in tumour burden at 4 weeks (p < 0.0001, two-way ANOVA). Conclusions: This study supports a role for increased PTTG1 expression in augmenting tumour development in a subset of MM patients.


Related Articles

  • Assessment of Bone Marrow Fibrosis and Angiogenesis in Monitoring Patients With Multiple Myeloma. Babarović, Emina; Valković, Toni; Štifter, Sanja; Budisavljević, Ivana; Seili-Bekafigo, Irena; Duletić-Načinović, Antica; Lučin, Ksenija; Jonjić, Nives // American Journal of Clinical Pathology;Jun2012, Vol. 137 Issue 6, p871 

    The aim of our study was to emphasize the importance of accurate and standardized techniques for detailed monitoring of the microenvironment in multiple myeloma (MM). Bone marrow fibrosis, angiogenesis, and plasma cell infiltrates in bone marrow biopsy (BMB) samples at the time of diagnosis and...

  • Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols. Usmani, S Z; Nair, B; Qu, P; Hansen, E; Zhang, Q; Petty, N; Waheed, S; Shaughnessy, J D; Alsayed, Y; Heuck, C J; van Rhee, F; Milner, T; Hoering, A; Szymonifka, J; Sexton, R; Sawyer, J; Singh, Z; Crowley, J; Barlogie, B // Leukemia (08876924);Nov2012, Vol. 26 Issue 11, p2398 

    To determine whether primary plasma cell leukemia (PPCL) remains a high-risk multiple myeloma feature in the context of contemporary therapy and gene-expression profiling (GEP), we reviewed records of 1474 patients with myeloma, who were enrolled in Total Therapy protocols or treated identically...

  • In pursuit of the allo-immune response in multiple myeloma: where do we go from here? Cook, G.; Bird, J. M.; Marks, D. I. // Bone Marrow Transplantation;Jan2009, Vol. 43 Issue 2, p91 

    AlloSCT is a potentially curative procedure for haematological malignancies and marrow failure syndromes. However, unlike leukaemia and lymphoproliferative disorders, AlloSCT has yet to find its place in the clinical management of patients with multiple myeloma. AlloSCT in multiple myeloma is...

  • Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Hideshima, Teru; Mitsiades, Constantine; Tonon, Giovanni; Richardson, Paul G.; Anderson, Kenneth C. // Nature Reviews Cancer;Aug2007, Vol. 7 Issue 8, p585 

    Multiple myeloma is a plasma cell malignancy characterized by complex heterogeneous cytogenetic abnormalities. The bone marrow microenvironment promotes multiple myeloma cell growth and resistance to conventional therapies. Although multiple myeloma remains incurable, novel targeted agents, used...

  • Multiple primary cutaneous plasmacytomas. Fitzhugh, V. A.; Siegel, D.; Bhattacharyya, P. K. // Journal of Clinical Pathology;Jun2008, Vol. 61 Issue 6, p782 

    The article offers information on multiple primary cutaneous plasmacytomas. Multiple myeloma and solitary plasmacytoma occur in the bone marrow and extramedullary sites such as upper respiratory and gastrointestinal tracts. Lesions are commonly found on the face, trunk and extremities....

  • The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma. Yao Zhang; Li Bao; Jin Lu; Kai-Yan Liu; Jin-Lan Li; Ya-Zhen Qin; Huan Chen; Ling-Di Li; Yuan Kong; Hong-Xia Shi; Yue-Yun Lai; Yan-Rong Liu; Bin Jiang; Shan-Shan Chen; Xiao-Jun Huang; Guo-Rui Ruan // Molecular Cancer;2014, Vol. 13 Issue 1, p1 

    Background Cancer-testis (CT) antigen genes might promote the progression of multiple myeloma (MM). CT antigens may act as diagnostic and prognostic markers in MM, but their expression levels and clinical implications in this disease are not fully understood. This study measured the expression...

  • Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. Nayar, Utthara; Sadek, Jouliana; Reichel, Jonathan; Hernandez-Hopkins, Denise; Akar, Gunkut; Barelli, Peter J.; Sahai, Michelle A.; Hufeng Zhou; Totonchy, Jennifer; Jayabalan, David; Niesvizky, Ruben; Guasparri, Ilaria; Hassane, Duane; Yifang Liu; Shizuko Sei; Shoemaker, Robert H.; Warren, J. David; Elemento, Olivier; Kaye, Kenneth M.; Cesarman, Ethel // Journal of Clinical Investigation;Jun2017, Vol. 127 Issue 6, p2066 

    Primary effusion lymphoma (PEL) is a largely incurable malignancy of B cell origin with plasmacytic differentiation. Here, we report the identification of a highly effective inhibitor of PEL. This compound, 6-ethylthioinosine (6-ETI), is a nucleoside analog with toxicity to PEL in vitro and in...

  • Genomic vulnerability to LINE-1 hypomethylation is a potential determinant of the clinicogenetic features of multiple myeloma. Aoki, Yuka; Nojima, Masanori; Suzuki, Hiromu; Yasui, Hiroshi; Maruyama, Reo; Yamamoto, Eiichiro; Ashida, Masami; Itagaki, Mitsuhiro; Asaoku, Hideki; Ikeda, Hiroshi; Hayashi, Toshiaki; Imai, Kohzoh; Mori, Mitsuru; Tokino, Takashi; Ishida, Tadao; Toyota, Minoru; Shinomura, Yasuhisa // Genome Medicine;2012, Vol. 4 Issue 12, p1 

    Background: The aim of this study was to clarify the role of global hypomethylation of repetitive elements in determining the genetic and clinical features of multiple myeloma (MM). Methods: We assessed global methylation levels using four repetitive elements (long interspersed nuclear element-1...

  • Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients. raja, Karthick raja Muthu; hajek, Roman // OncoImmunology;Sep2013, Vol. 2 Issue 9, pe25619-1 

    Multiple myeloma (MM) patients exhibit consistent degrees of immune dysfunction. regulatory T cells contribute to the establishment of an immunosuppressive status in MM patients, hence favoring disease progression.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics